^
Association details:
| Biomarker: | AKR1C1 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma
Published date:
06/30/2023
Excerpt:
The overall survival rates of patients in the high AKR1C1 expression group were significantly lower than those in the low AKR1C1 expression group…
DOI:
10.21037/jgo-23-277
